TRK inhibitors are the first agnostic tumor targeted therapy approved by the regulatory authority, and are the best model for tumor precision medicine, especially for the development of a novel “basket trial.”50 Larotrectinib and entrectinib are the first FDA‐approved TRK inhibitors for treating pan‐cancer patients with NTRK1/2/3 gene fusions. Here, TPM3 is linked to neoplasm.